Pharming Group N.V. PHAR
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 90.21M | 72.45M | 106.53M | 97.29M | 93.22M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 90.21M | 72.45M | 106.53M | 97.29M | 93.22M |
| Cost of Revenue | 14.55M | 6.64M | 21.13M | 7.07M | 8.97M |
| Gross Profit | 75.67M | 65.80M | 85.40M | 90.22M | 84.25M |
| SG&A Expenses | 43.52M | 45.53M | 50.67M | 43.08M | 51.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1.42M | -377.00K | -348.00K | -71.00K | -1.85M |
| Total Operating Expenses | 88.90M | 77.36M | 103.50M | 71.37M | 82.37M |
| Operating Income | 1.31M | -4.91M | 3.03M | 25.92M | 10.85M |
| Income Before Tax | 3.04M | -4.75M | 4.80M | 12.76M | 7.08M |
| Income Tax Expenses | 1.40M | 459.00K | -528.00K | 5.21M | 2.53M |
| Earnings from Continuing Operations | 1.64M | -5.21M | 5.33M | 7.55M | 4.55M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | 0.00 | 0.00 | 144.00K |
| Net Income | 1.64M | -5.21M | 5.33M | 7.55M | 4.69M |
| EBIT | 1.31M | -4.91M | 3.03M | 25.92M | 10.85M |
| EBITDA | 2.67M | -1.80M | 6.24M | 30.12M | 12.08M |
| EPS Basic | 0.00 | -0.01 | 0.01 | 0.02 | 0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | -- | 0.01 |
| EPS Diluted | 0.00 | -0.01 | 0.01 | 0.02 | 0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | -- | 0.01 |
| Average Basic Shares Outstanding | 666.05M | 744.71M | 662.50M | 502.26M | 686.44M |
| Average Diluted Shares Outstanding | 666.05M | 744.71M | 757.14M | 502.26M | 686.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |